Invokana Renal Outcomes

Prescribing Information

Great Britain Northern Ireland

Exploratory Renal Outcomes

In patients who do not meet the criteria for diabetic kidney disease (eGFR >60 mL/min/1.73 m², UACR < 30 mg/mmol), Invokana reduces protein in the urine and the risk of Major Adverse Renal Events (MARE), defined as doubling of serum creatinine, need for renal replacement therapy or renal death, compared to placebo...

Learn more about the CREDENCE study and renal benefits in T2DM patients with DKD

…while stabilising eGFR levels for the long term.^1,2

With standard of care, eGFR declines over time. After an initial fall in mean eGFR during the first 4 weeks of treatment, Invokana stabilises eGFR levels for the long term.²

Guideline Recommendations

Abbreviations

ARR: Absolute Risk Reduction; eGFR: estimated Glomerular Filtration Rate; HR: Hazard Ratio; MARE: Major Adverse Renal Events; SoC: Standard of Care; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/Creatinine Ratio.

References

Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
Perkovic V, de Zeeuw D, Mahaffey K et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. The Lancet Diabetes & Endocrinology. 2018;6(9):691-704. doi:10.1016/s2213-8587(18)30141-4.

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.